Educational sessions on the INTERPHEX show floor will include a panel discussion on implementing continuous manufacturing.
Pharmaceutical Technology will present the INTERPHEX Keynote Series: Oral Solid Dosage Continuous Manufacturing Panel Discussion on Tuesday, April 2, 2019 at 10:30 am. The session will be held on the show floor at the Innovation Stage and is open to all show attendees.
Several solid-dosage drugs are now approved for manufacture using continuous processes, and early adopters and equipment manufacturers have been making progress in addressing engineering challenges. Two of the potential advantages of continuous manufacturing compared to batch manufacturing are rapid development and flexibility in scale. This panel discussion will consider what benefits are being realized and what challenges are arising as continuous processes are commercialized. Experts will discuss best practices for and challenges in tech transfer and scale-up/scale-out from development to commercial scale.
Moderator: Jennifer Markarian, Pharmaceutical Technology
Panel participants:
Gregory Connelly, director in formulation development and drug product continuous manufacturing lead, Vertex Pharmaceuticals
José Luis Santos, PhD, Head of Operations, Drug Product Continuous Manufacturing at Hovione
Doug Hausner, PhD, Associate Director for the Engineering Research Center for Structured Organic Particulate Systems (C-SOPS) based at Rutgers University
Sharon Nowak, Global Business Development Manager, Food and Pharmaceuticals, Coperion K-Tron
Learn more
Click here to see more show information.
Click here and use promo code IPXREG to register for INTERPHEX.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.